Researchers from the Hospital Universitari Vall d’Hebron and colleagues have reported on the development of Hybri, a hybrid recombinant bispecific fusion protein with immunosuppressive activity that consists of the extracellular domain (ECD) of human PD-L2 fused via a linker to the ECD of human CTLA-4, further fused to the Fc domain of human IgG.
New and updated preclinical and clinical data presented by biopharma firms at the American Society of Clinical Oncology annual meeting, including: Agenus, Akeso, Alligator, Arcus, Atara, Bold, Coherus, Dragonfly, Ellipses, Erasca, Fulgent Genetics, Galera, Gilead, Gilead Sciences, Gracell, Iaso, Immunocore, Immunogen, Immutep, Innovent Biologics, Intensity, ISA, Janssen, Kite, Linnaeus, Memgen, NEC, Precigen, Transcenta, Transgene.
Since accelerated approvals first began to be granted in 1992, their pace for cancer indications has increased dramatically but a revolution in science has made it tough for the U.S. FDA to find its balance.
Researchers from Beijing Corregene Biotechnology Co. Ltd. presented preclinical data for CRTE7A2-01, a cell therapy candidate consisting of human T cells expressing T-cell receptors (TCRs) specific for HLA-A*02:01-restricted HPV16 E7 antigen.
CD38 is an enzyme with NAD-depleting and intracellular signaling activity expressed on the cell surface, in intracellular compartments and in mitochondria, and is linked to inflammatory and autoimmune diseases. Studies in CD38-deficient mice have revealed that these animals develop a type of collagen-induce arthritis (CIA) which suggests a link between CD38 and CIA pathogenesis.
Glucocorticoids are very effective immunosuppressive and anti-inflammatory drugs that cause dose-limiting toxicities in brain, liver and bone preventing their use mainly in chronic disorders. Researchers from Immunext Inc. recently reported results from the therapeutic evaluation of the nontoxic glucocorticoid INX-200 with anti-inflammatory efficacy in a once-per-month injection.
Breakthroughs in early detection of cancer offer increasing hope for better outcomes and longer lives for individuals affected by malignancies. This year’s American Society of Clinical Oncology annual meeting highlighted strong results from several companies at the forefront of this potential transformation.
In the flurry of presentations on early detection of cancer at the 2023 American Society of Clinical Oncology Annual Meeting, Grail LLC stood out for the number of sessions and the strength of its results. In a real-world study presented, Grail’s Galleri multi-cancer early detection (MCED) test cancer signal origin (CSO) demonstrated accuracy of 91%.
When combined with chemotherapy, the PD-1 inhibitor antibody toripalimab reduced the risk of death by 37% over chemotherapy alone when used first line in patients with recurrent or metastatic nasopharyngeal carcinoma, Coherus Biosciences Inc. revealed at this year’s American Society of Clinical Oncology meeting (ASCO).
Despite the title of the Sunday, June 4 lead-off presentation at the American Society of Clinical Oncology (ASCO) meeting in Chicago, there was little room left for doubt about the increasingly important place of artificial intelligence (AI) in drug development.
RSS
